Previous studies have shown that the mutation rate of KRAS in patients with CRC is 37%–56%, and the mutation status is related to tumor size, tumor location, degree of tumor differentiation, lymph node metastasis, and other factors (13–16). This evidence concerns the gene KRAS and colorectal carcinoma.